Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials.

@article{BoscoloBerto2012NarcolepsyAE,
  title={Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials.},
  author={Rafael Boscolo-Berto and Guido Viel and Sara Montagnese and Daniella I Raduazzo and Santo Davide Ferrara and Yves Dauvilliers},
  journal={Sleep medicine reviews},
  year={2012},
  volume={16 5},
  pages={
          431-43
        },
  url={https://api.semanticscholar.org/CorpusID:34282971}
}
View on PubMed
doi.org
117 Citations
Highly Influential Citations
2
Background Citations
40
Methods Citations
5
Results Citations
2

117 Citations

Gamma-hydroxybutyrate (GHB) for narcolepsy in adults: an updated systematic review and meta-analysis.

Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial

An evaluation of sodium oxybate as a treatment option for narcolepsy

Sodium oxybate improves narcolepsy symptoms and enhances quality of life in narcoLEpsy patients and is an effective therapy for disrupted nocturnal sleep.

Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis

All approved interventions were effective in controlling the symptoms of narcolepsy at varying degrees with an acceptable safety profile.

Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.

Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy

The aim of this review is to discuss and summarize the main therapeutic strategies for the management of excessive daytime sleepiness (EDS) in patients with narcolepsy. An overview of novel therapies…

Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy

The review confirmed the effectiveness of pitolisant in treating major clinically relevant narcolepsy symptoms, including cataplexy, as compared to placebo and revealed a safe profile when compared with placebo and active comparators.

Sodium oxybate (Xyrem®): A new and effective treatment for narcolepsy with cataplexy

Sodium oxybate improved sleep architecture by increasing delta power and the duration of slow-wave sleep and by reducing nocturnal awakenings in patients with narcolepsy with cataplexy and global function and health-related quality of life were improved by SXB.

Effect of Repeated Administration of ɣ-Valerolactone (GVL) and GHB in the Mouse: Neuroadaptive Changes of the GHB and GABAergic System

A new methodological strategy is provided for better understanding the properties of this controversial substance, which could help to better grasp the unknown mechanism underlying its abuse profile.

The behavioural profile of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol in humans

...

39 References

Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings.

It is noteworthy, therefore, that the central biochemical changes induced by GHB also appear comparable to those found naturally in narcolepsy.

The Effects of "1-Hydroxybutyrate on the Sleep of Narcolepsy Patients: A Double-Blind Study.

It is conjectured that GHB, an endogenous neurochemical, may be a sleep neurotransmitter or neuromodulator, since GHB rapidly induces sleep, and increases sleep continuity and delta sleep without suppressing REM sleep in both normals and narcolepsy patients.

EFNS guidelines on management of narcolepsy

A task force composed of the leading specialists of narcolepsy in Europe conducted an extensive review of pharmacological and behavioral trials available in the literature to reinforce the use of those drugs evaluated in randomized placebo‐controlled trials and to reach a consensus, as much as possible, on theUse of other available medications.

Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: Double-blind subjective measures

Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study.

It is concluded that GHB is an effective and well-tolerated treatment for narcolepsy and tends to increase slow wave sleep.

A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy.

The nightly administration of sodium oxybate produced significant dose-related improvements in the Total Functional Outcomes of Sleep Questionnaire score, as well as in the Activity Level, General Productivity, Vigilance, and Social Outcomes subscales.

The Treatment of Narcolepsy-Cataplexy with Nocturnal Gamma-Hydroxybutyrate

The subjective quality of night sleep improved in all patients and the number of irresistable daytime attacks of sleep and cataplexy substantially diminished, and improvement has been maintained for up to 20 months without the development of tolerance.

The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy.

The number of nightly awakenings significantly decreased, while Stages 3 and 4 sleep substantially increased, and daytime sleepiness, while not completely eliminated, was controlled with lower doses of stimulant medication than patients were taking before the study.

Effects of Nocturnal Gamma-Hydroxybutyrate on Sleep/Waking Patterns in Narcolepsy-Cataplexy

GBH improved the quality of night sleep by increasing the amount of slow wave sleep, reducing stage I, increasing sleep efficiency, and reducing the number of periods of short sleep under 15 minutes.

Treatment of narcolepsy and other hypersomnias of central origin.

The strengths and limitations of the available evidence regarding treatment of narcolepsy and other hypersomnias of central origin are discussed, and key information about safety of these medications is summarized.